IRAK3 and type 2 diabetes mellitus: This cGMP-mediated pathway may represent a novel mechanism by which IRAK3 exerts its anti-inflammatory effects, providing new therapeutic avenues for managing inflammatory responses in T2DM and MAFLD (66, 73).